Overview

A Study of STAR-0215 in Participants With Hereditary Angioedema

Status:
Not yet recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and the other group will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Astria Therapeutics, Inc.